Dirlotapide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. | Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. | ||
Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog's weight. | Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog's weight. | ||
== References == | == References == | ||
Latest revision as of 15:55, 7 April 2015
|
WikiDoc Resources for Dirlotapide |
|
Articles |
|---|
|
Most recent articles on Dirlotapide Most cited articles on Dirlotapide |
|
Media |
|
Powerpoint slides on Dirlotapide |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Dirlotapide at Clinical Trials.gov Clinical Trials on Dirlotapide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Dirlotapide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Dirlotapide Discussion groups on Dirlotapide Patient Handouts on Dirlotapide Directions to Hospitals Treating Dirlotapide Risk calculators and risk factors for Dirlotapide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Dirlotapide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Dirlotapide is a drug used to treat obesity in dogs. It is manufactured by Pfizer and marketed as Slentrol.
It works as a selective microsomal triglyceride transfer protein (MTTP) inhibitor. This blocks the assembly and release of lipoproteins into the bloodstream, thereby reducing fat absorption. It also elicits a satiety signal from lipid-filled cells lining the intestine.
It is supplied as an oral solution. It is not intended for use in humans, cats, or parrots.
On January 5, 2007, the U.S. Food and Drug Administration (FDA) approved Slentrol, the first time the FDA has approved a drug for obese dogs. Dirlotapide is used to manage obesity in dogs and helps by reducing appetite. It should be used as part of an overall weight control program that also includes proper diet and exercise, under the supervision of a veterinarian. Side effects may include vomiting, diarrhea, lethargy, drooling, or uncoordination. Allergic reaction to the medication may include, facial swelling, hives, scratching, sudden onset of diarrhea, vomiting, shock, seizures, pale gums, cold limbs, or coma. Contact your veterinarian if you observe any of these signs. The dose of dirlotapide will need to be recalculated each month, based on your dog's weight.
References
Template:Antiobesity preparations Template:Lipid modifying agents